Kuo P T, Fan W C, Kostis J B, Hayase K
Circulation. 1976 Feb;53(2):338-41. doi: 10.1161/01.cir.53.2.338.
The hypolipidemic effect of PAS-C-diet treatment was studied in 63 patients with Types IIa and IIb hyperlipoproteinemia for 6-36 months. Serum lipids and body weights of all patients were stabilized by a low cholesterol-saturated fat-refined carbohydrate diet before the initiation of an eight-week placebo-drug single-blind crossover study. During the placebo period the plasma lipids levels, mean +/- SD: cholesterol 355 +/- 63.5 mg%, triglyceride 141 +/- 68.7 mg%, and LDL-cholesterol 279 +/- 56.8 mg% were lowered to 274 +/- 53.1 mg+, 98 +/- 40.6 mg%, and 209 +/- 52.9 mg%, respectively (P less than 0.001 in each instance), with 7.5-11.0 grams of PAS-C/day given in one to three divided doses. In ten patients who have completed three years of treatment similar results were obtained. They showed no tendency to develop drug tolerance. Eight had watery diarrhea during the initial period which promptly subsided with interruption of drug therapy. Reintroduction of PAS-C in smaller dose (4.5 g/day) with gradual increment to effective dosage level was tolerated by all. No hematologic, hepatic, and ophthalmologic abnormalities were demonstrated by periodic monitoring. The hypoplipidemic effect of the drug was found to be diminished by alcohol and caloric excess.
对63例IIa型和IIb型高脂蛋白血症患者进行了为期6至36个月的对氨基水杨酸钙(PAS-C)饮食治疗降血脂作用的研究。在为期八周的安慰剂-药物单盲交叉研究开始前,通过低胆固醇-饱和脂肪-精制碳水化合物饮食使所有患者的血脂和体重稳定。在安慰剂期,血浆脂质水平,均值±标准差:胆固醇355±63.5mg%,甘油三酯141±68.7mg%,低密度脂蛋白胆固醇279±56.8mg%,分别降至274±53.1mg%、98±40.6mg%和209±52.9mg%(各情况P均小于0.001),每日给予1至3次共7.5 - 11.0克PAS-C。在完成三年治疗的10例患者中获得了类似结果。他们未表现出产生药物耐受性的倾向。8例在初始阶段出现水样腹泻,药物治疗中断后迅速消退。所有患者均耐受以较小剂量(4.5克/天)重新引入PAS-C并逐渐增加至有效剂量水平。定期监测未发现血液学、肝脏和眼科异常。发现酒精和热量摄入过多会减弱该药物的降血脂作用。